Clinical Trial Detail

Ibrutinib and Obinutuzumab With or Without Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia

Complete title: A Randomized Phase III Study of the Addition of Venetoclax to Ibrutinib and Obinutuzumab Versus Ibrutinib and Obinutuzumab in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)

Research Study Number	RG1005116
Principal Investigator	Mazyar Shadman
Phase	III

Look up trial at NIH

Research Study Description

This phase III trial studies how well ibrutinib and obinutuzumab with or without venetoclax work in treating patients with chronic lymphocytic leukemia. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as obinutuzumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as venetoclax, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving ibrutinib, obinutuzumab and venetoclax may work better in treating patients with chronic lymphocytic leukemia.

Eligibility Criteria (must meet the following to participate in this study)

** For Eligibility information, please click on the "Look up trial at NIH" link above **

Other eligibility criteria may apply.

Research Study Number	RG1005116
Contact	Seattle Cancer Care Alliance Intake Office
Telephone	800-804-8824 / 206-606-1024

Keywords: Leukemia, Chronic Lymphocytic (CLL); Leukemia, B-Cell; Lymphoma, Small Lymphocytic (SLL); Leukemia, Lymphocytic, Chronic, B-Cell; Immune System Diseases

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:

Talk to your health care providers first before making decisions about your health care.

Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.

RSS feed

Last Modified, June 25, 2019